526 related articles for article (PubMed ID: 18232531)
1. [ESBL--increasing resistance problems. Cephalosporins no longer obvious choice in diffuse infections].
Hallgren H; Gustafsson I; Ripa T
Lakartidningen; 2007 Dec; 104(51-52):3883-5. PubMed ID: 18232531
[No Abstract] [Full Text] [Related]
2. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of extended-spectrum beta-lactamases.
Rodríguez-Baño J; Pascual A
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):671-83. PubMed ID: 18847405
[TBL] [Abstract][Full Text] [Related]
4. Resistance in gram-negative bacteria: enterobacteriaceae.
Paterson DL
Am J Med; 2006 Jun; 119(6 Suppl 1):S20-8; discussion S62-70. PubMed ID: 16735147
[TBL] [Abstract][Full Text] [Related]
5. [Extended-spectrum of beta-lactamases (ESBL): yesterday ESBL: and today ESBL, carbapenemase-producing and multiresistant bacteria].
Ghebremedhin B
Dtsch Med Wochenschr; 2012 Dec; 137(50):2657-62. PubMed ID: 23225190
[TBL] [Abstract][Full Text] [Related]
6. Extended-spectrum beta-lactamases. An overview.
Patterson JE
Postgrad Med; 2001 Feb; 109(2 Suppl):32-8. PubMed ID: 19667555
[TBL] [Abstract][Full Text] [Related]
7. Extended-spectrum beta-lactamases and clinical outcomes: current data.
Ramphal R; Ambrose PG
Clin Infect Dis; 2006 Apr; 42 Suppl 4():S164-72. PubMed ID: 16544267
[TBL] [Abstract][Full Text] [Related]
8. Extended-spectrum beta-lactamases in Enterobacteriaceae: related to age and gender.
Shah AA; Hasan F; Ahmed S; Hameed A
New Microbiol; 2002 Jul; 25(3):363-6. PubMed ID: 12173781
[TBL] [Abstract][Full Text] [Related]
9. Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae.
de La Blanchardière A; Dargère S; Guérin F; Daurel C; Saint-Lorant G; Verdon R; Cattoir V
Med Mal Infect; 2015 May; 45(5):169-72. PubMed ID: 25845927
[TBL] [Abstract][Full Text] [Related]
10. Distribution of ESBL-producing enterobacteria associated to community-acquired monomicrobial urinary tract infections and antimicrobial susceptibility trends over a 9-year period.
Dias VC; da Silva VL; Firmo Ede O; Bastos LQ; Bastos AN; Bastos RV; Diniz CG
J Chemother; 2012 Jun; 24(3):178-81. PubMed ID: 22759764
[No Abstract] [Full Text] [Related]
11. Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae.
Muratani T; Matsumoto T
Int J Antimicrob Agents; 2006 Aug; 28 Suppl 1():S10-3. PubMed ID: 16829056
[TBL] [Abstract][Full Text] [Related]
12. Which proportion of extended-spectrum beta-lactamase producing strains could be treated by non-carbapenem beta-lactams?
Canoui E; Tankovic J; Bige N; Alves M; Offenstadt G
Med Mal Infect; 2014 May; 44(5):235-7. PubMed ID: 24780641
[No Abstract] [Full Text] [Related]
13. Outcome of urinary tract infections caused by extended spectrum β-lactamase-producing Enterobacteriaceae in children.
Tratselas A; Iosifidis E; Ioannidou M; Saoulidis S; Kollios K; Antachopoulos C; Sofianou D; Roilides EJ
Pediatr Infect Dis J; 2011 Aug; 30(8):707-10. PubMed ID: 21248655
[TBL] [Abstract][Full Text] [Related]
14. Carbapenemase-producing enterobacteriaceae (CPE) in the pediatric setting: results from an 18-month survey.
Colombo S; Scolfaro C; Calitri C; Denina M; Carraro F; De Intinis G; Tovo PA
Infect Control Hosp Epidemiol; 2014 May; 35(5):599-601. PubMed ID: 24709738
[No Abstract] [Full Text] [Related]
15. [Estimation of the contribution of the small plasmids in creation of ESBL phenotype among clinical and ambulatory isolates of the Enterobacteriaceae].
Nieradko J
Med Dosw Mikrobiol; 2007; 59(3):223-30. PubMed ID: 18078117
[TBL] [Abstract][Full Text] [Related]
16. [Monitoring of resistance to chemotherapeutics of enterobacteria strains isolated from urocultures from out-patients].
Nicodemus T; Văduva DB; Adămuţ M; Linţa M; Velimirovici D; Orb CE; Păun M; Moldovan R
Bacteriol Virusol Parazitol Epidemiol; 2005; 50(1-2):49-57. PubMed ID: 17300031
[TBL] [Abstract][Full Text] [Related]
17. Novel plasmid-mediated beta-lactamases in enterobacteriaceae: emerging problems for new beta-lactam antibiotics.
Thomson KS; Prevan AM; Sanders CC
Curr Clin Top Infect Dis; 1996; 16():151-63. PubMed ID: 8714252
[No Abstract] [Full Text] [Related]
18. Addressing the challenge of extended-spectrum beta-lactamases.
Zahar JR; Lortholary O; Martin C; Potel G; Plesiat P; Nordmann P
Curr Opin Investig Drugs; 2009 Feb; 10(2):172-80. PubMed ID: 19197795
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic resistance in adult female patients hospitalized for acute pyelonephritis: rates and predicting factors.
Etienne M; Van Elslande H; Choplin-Renard J; Pestel-Caron M; Caron F
Med Mal Infect; 2014 May; 44(5):217-22. PubMed ID: 24787633
[TBL] [Abstract][Full Text] [Related]
20. Extended-spectrum beta-lactamases in ambulatory care: a clinical perspective.
Rodríguez-Baño J; Navarro MD
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():104-10. PubMed ID: 18154533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
